ABCG2 overexpression
|
Osteosarcoma
|
ABCG2 overexpression
|
Osteosarcoma
|
MAP Resistant: C3 – Early Trials
|
MAP Resistant: C3 – Early Trials
|
ABCG2 overexpression
|
Head and Neck Cancer
|
ABCG2 overexpression
|
Head and Neck Cancer
|
paclitaxel Resistant: C3 – Early Trials
|
paclitaxel Resistant: C3 – Early Trials
|
ABCG2 overexpression
|
Breast Cancer
|
ABCG2 overexpression
|
Breast Cancer
|
paclitaxel Resistant: D – Preclinical
|
paclitaxel Resistant: D – Preclinical
|
ABCG2 overexpression
|
CRC
|
ABCG2 overexpression
|
CRC
|
oxaliplatin Resistant: D – Preclinical
|
oxaliplatin Resistant: D – Preclinical
|
ABCG2 overexpression
|
CRC
|
ABCG2 overexpression
|
CRC
|
PF-05212384 Resistant: D – Preclinical
|
PF-05212384 Resistant: D – Preclinical
|
ABCG2 overexpression
|
Solid Tumor
|
ABCG2 overexpression
|
Solid Tumor
|
TP-3654 + IT-141 Sensitive: D – Preclinical
|
TP-3654 + IT-141 Sensitive: D – Preclinical
|
ABCG2 overexpression
|
Solid Tumor
|
ABCG2 overexpression
|
Solid Tumor
|
mitoxantrone + TP-3654 Sensitive: D – Preclinical
|
mitoxantrone + TP-3654 Sensitive: D – Preclinical
|
ABCG2 overexpression
|
Solid Tumor
|
ABCG2 overexpression
|
Solid Tumor
|
topotecan + TP-3654 Sensitive: D – Preclinical
|
topotecan + TP-3654 Sensitive: D – Preclinical
|